Home Biosimilar Antibodies Others Others Pozelimab (Anti-Complement C5)
For research use only. Not for use in humans.

Pozelimab (Anti-Complement C5)

Synonyms: C5

Pozelimab (Anti-Complement C5) is a fully human IgG4 monoclonal antibody targeting C5. It can be used for the research of complement-mediated diseases. MW :144.78 KD.

Pozelimab (Anti-Complement C5)

Quality Control

Batch: A301601 Purity: 99% Protein concentration: 6.51mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Pozelimab (Anti-Complement C5) is a fully human IgG4 monoclonal antibody targeting C5. It can be used for the research of complement-mediated diseases. MW :144.78 KD.
References

Product Details

CAS No. 2096328-94-6
Isotype Human IgG4SP
Source CHO
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07142343 RECRUITING Drug: Pozelimab CHAPLE Disease Regeneron Pharmaceuticals 2026-03-19 PHASE4
NCT07154745 RECRUITING Drug: Pozelimab|Drug: Cemdisiran Paroxysmal Nocturnal Hemoglobinuria Regeneron Pharmaceuticals 2026-06-11 PHASE3
NCT07520318 NOT_YET_RECRUITING Drug: bispecific anti-VEGF and anti-complement Adults With Neovascular Age-related Macular Degeneration Shenzhen Oculgen Biomedical Technology Co., Ltd. 2026-04-17 PHASE2; PHASE3
NCT05744921 RECRUITING Drug: Pozelimab|Drug: Cemdisiran Paroxysmal Nocturnal Hemoglobinuria Regeneron Pharmaceuticals 2023-03-07 PHASE3
NCT06541704 RECRUITING Drug: Pozelimab|Drug: Cemdisiran|Drug: Placebo Age-related Macular Degeneration (AMD); Geographic Atrophy (GA) Regeneron Pharmaceuticals 2024-10-30 PHASE3
NCT07230834 RECRUITING Drug: Pozelimab Geographic Atrophy (GA) Regeneron Pharmaceuticals 2026-01-19 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-04-13)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.